만성폐쇄성폐질환(COPD) : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

Thelansis's "Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a major global cause of chronic morbidity and mortality, currently ranking among the leading causes of death worldwide. The disease is characterized by persistent airflow limitation resulting from chronic inflammation, airway remodeling, and progressive destruction of lung parenchyma.

Pathophysiologically, COPD involves narrowing of small airways, loss of alveolar attachments, and reduced lung elasticity, which impair airflow, particularly during exhalation. This leads to air trapping, reduced gas exchange, and progressive respiratory dysfunction.

Diagnosis is confirmed using spirometry, with a post-bronchodilator FEV1/FVC ratio <0.70 indicating airflow obstruction. However, disease burden is not solely determined by airflow limitation; symptom severity (e.g., dyspnea, cough) and frequency of exacerbations play a critical role in clinical assessment.

Modern COPD management follows a multidimensional approach, combining spirometric classification with symptom burden and exacerbation risk to guide therapy. Treatment includes bronchodilators (LABA/LAMA), inhaled corticosteroids (ICS), and supportive care, aimed at reducing symptoms, preventing exacerbations, and improving quality of life.

Key Highlights

• COPD is a high-prevalence, chronic respiratory disease with significant global mortality burden
• US prevalent population expected to grow from ~28.1M to ~33.0M (~1.6% CAGR)

Market Overview

• Spain (mild-to-moderate segment) market projected to grow from ~$219M to ~$231M (~0.5% CAGR)
• Growth remains modest, driven by generic inhalation therapies and stable disease prevalence, with limited breakthrough innovation

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios S.A.
• AstraZeneca
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma (shanghai) Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell (Shanghai) Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp & Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici S.p.A.
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)